SB 415286, > = 98 %(HPLC)

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

SB 415286 was used to treat neuroblastoma cells and study the effect of GSK-3 inhibition on cell proliferation.

Biochem/physiol Actions

SB 415286 is a small molecule inhibitor of GSK-3 in muscle and fat cells. SB 415286 induces activation of glycogen synthase and regulates the transport glucose. SB 415286 reduces the systemic inflammation induced by endotoxic shock in rat model of acute colitis. It increases the axonal growth and promotes the recovery of injured adult CNS neurons. SB 415289 is implicated in inducing chromosome instability when used as therapeutic agents.

Glycogen synthase kinase-3 (GSK-3) inhibitor.

Features and Benefits

This compound is featured on the GSK-3 and PKB/Akt pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline.

Packaging

5, 25 mg in glass bottle